Table 2.
The 20 most frequent recurring copy number aberrations in childhood leukemia, as detected by molecular inversion probes
Lineage-specific cases, % | |||||||||
---|---|---|---|---|---|---|---|---|---|
Cases, no. | Typea | Chr | Location | Ref.b | Length bp | B-ALL (n = 23) | T-ALL (n = 6) | AML (n = 14) | Genes in regionc |
23 | Loss | 16 | 16q22.3 | – | 10352 | 44 | 83 | 50 | MLKL |
Gain | 16 | 16q22.3 | – | – | 4 | – | – | MLKL | |
22 | Loss | 10 | 10q25.2 | – | 2490 | 57 | 67 | 36 | ADRA2A |
19 | Loss | 7 | 7q21.13 | – | 1363 | 35 | 67 | 43 | FZD1 |
Gain | 7 | 7q21.13 | – | – | 4 | – | – | FZD1 | |
19 | Loss | 17 | 17p13.1 | [10] | 1978 | 17 | 17 | 36 | none known |
Gain | 17 | 17p13.1 | – | – | 26 | 17 | 14 | none known | |
17 | Loss | 14 | 14q24.2 | [10] | 270 | 30 | 50 | 36 | none known |
Gain | 14 | 14q24.2 | – | – | 9 | – | – | none known | |
16 | Loss | 4 | 4p16.3 | – | 79037 | 9 | – | 14 | TACC3 |
Gain | 4 | 4p16.3 | – | – | 26 | 33 | 29 | TACC3 | |
15 | Loss | 21 | 21q22.11 | [11] | 7219 | 4 | – | 7 | OLIG2 |
Gain | 21 | 21q22.11 | – | – | 30 | 17 | 36 | OLIG2 | |
15 | Loss | 5 | 5q35.3 | – | 18679 | 17 | 67 | 50 | CLK4 |
15 | Loss | 1 | 1p36.12 | – | 203480 | 44 | 50 | 14 | EIF4G3, HP1BP3, SH2D5, KIF17, DDOST |
14 | Loss | 6 | 6p22.1 | – | 717 | 9 | – | 7 | none known |
Gain | 6 | 6p22.1 | – | – | 26 | 17 | 29 | none known | |
14 | Loss | 9 | 9p21.3 | [10,11] | 24424 | 35 | 100 | – | CDKN2A |
13 | Loss | 11 | 11q13.2 | – | 3454 | 22 | 33 | 36 | none known |
Gain | 11 | 11q13.2 | – | – | 4 | – | – | none known | |
13 | Gain | 2 | 2q31.1 | – | 12837 | 30 | 33 | 29 | HOXD13 |
12 | Loss | 2 | 2q35 | – | 2774 | 9 | 17 | 36 | FEV |
Gain | 2 | 2q35 | – | – | 4 | 17 | 14 | FEV | |
12 | Loss | 1 | 1p35.1 | – | 25184 | 4 | 17 | 7 | MARCKSL1 |
Gain | 1 | 1p35.1 | – | – | 22 | 17 | 21 | MARCKSL1 | |
13 | Loss | 8 | 8p12~p11.2 | – | 938 | 17 | 33 | 7 | ADRB3 |
Gain | 8 | 8p12~p11.2 | – | – | 13 | – | 21 | ADRB3 | |
13 | Loss | 14 | 14q32.32.32.33 | – | 1223220 | 4 | – | 14 | >5 genes |
Gain | 14 | 14q32.32~32.33 | – | – | 26 | 17 | 21 | >5 genes | |
12 | Gain | 21 | 21q22.2 | [10] | 423958 | 48 | 17 | – | ETS2, FLJ45139, PSMG1d |
11 | Loss | 14 | 14q11.2 | – | 280777 | 17 | 50 | – | none known |
Gain | 14 | 14q11.2 | – | – | 9 | – | 14 | none known | |
11 | Loss | 17 | 17q12 | – | 29229 | 9 | 17 | 21 | MLLT6 |
Gain | 17 | 17q12 | – | – | 13 | – | 14 | MLLT6 |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Chr, chromosome; CNA, copy number aberration; Ref., references.
Loss is defined as copy number ≤ 1.2. Gain is defined as copy number ≥ 2.8.
Based on > 1,000 genes involved in cancer development: oncogenes, tumor suppressors, DNA repair genes, cell growth genes, and metabolism genes.
The PSMG1 gene was previously described as DSCR2.